ACIU on Nasdaq

AC Immune SA

$2.44 up 0.04 (1.46%)Price as of Oct 15, 2026 at 17:33 UTC

Last updated Oct 16, 2026.

Overview

3.6MRevenue, fiscal 20253
-70.4MNet income, fiscal 20253

Compare with MindMaze Therapeutics Holding SA or Altamira Therapeutics Ltd., or pick any stock.

  • TickerACIU on Nasdaq
  • IndustryPharmaceutical Preparations
  • HeadquartersV8
  • Incorporated inSwitzerland4
  • Business addressEpfl Innovation Park, Building B, 1015 Lausanne, V8 000004
  • Filer categoryAccelerated filer4

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from. Figures are in CHF, the currency the company reports in.

Key numbers, fiscal 2025

-1940.1%Operating margin3
-1971.6%Net margin3
-86.9%Revenue growth, 20253
-157.0%Return on equity3
-70.2M CHFFree cash flow3

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Other costs100¢3.6M CHF

Out of 3.6M CHF in revenue.3 The company lost money this year.

Financial statements

Revenue5678933.6M CHF in 2025−48% since 2018
050.0M CHF100.0M CHF150.0M CHF2018: 6.9M CHF6.9M CHF20182019: 110.5M CHF110.5M CHF2019+1498%2020: 15.4M CHF15.4M CHF2020−86%2021: 0 CHF0 CHF20212022: 3.9M CHF3.9M CHF20222023: 14.8M CHF14.8M CHF2023+276%2024: 27.3M CHF27.3M CHF2024+85%2025: 3.6M CHF3.6M CHF2025−87%
Operating income567893-69.3M CHF in 2025+40% since 2018
-100.0M CHF-50.0M CHF050.0M CHF2018: -49.5M CHF-49.5M CHF20182019: 44.5M CHF44.5M CHF20192020: -61.3M CHF-61.3M CHF20202021: -79.0M CHF-79.0M CHF2021+29%2022: -70.8M CHF-70.8M CHF2022−10%2023: -53.6M CHF-53.6M CHF2023−24%2024: -52.4M CHF-52.4M CHF2024−2%2025: -69.3M CHF-69.3M CHF2025+32%
Net income567893-70.4M CHF in 2025+38% since 2018
-100.0M CHF-50.0M CHF050.0M CHF2018: -51.0M CHF-51.0M CHF20182019: 45.4M CHF45.4M CHF20192020: -61.9M CHF-61.9M CHF20202021: -73.0M CHF-73.0M CHF2021+18%2022: -70.8M CHF-70.8M CHF2022−3%2023: -54.2M CHF-54.2M CHF2023−23%2024: -50.9M CHF-50.9M CHF2024−6%2025: -70.4M CHF-70.4M CHF2025+38%

Every line of the income statement in the latest annual report, as filed.3

Period ending2025-12-312024-12-312023-12-31
Contract revenue3.6M CHF27.3M CHF14.8M CHF
Total revenue3.6M CHF27.3M CHF14.8M CHF
Research & development expenses-56.4M CHF-62.6M CHF-54.6M CHF
General & administrative expenses-16.1M CHF-17.3M CHF-15.3M CHF
Other operating income/(expense), net94.0K CHF142.0K CHF1.5M CHF
Restructuring expenses, net-455.0K CHF
Total operating expenses-72.9M CHF-79.7M CHF-68.4M CHF
Operating loss-69.3M CHF-52.4M CHF-53.6M CHF
Financial income1.9M CHF3.2M CHF1.0M CHF
Financial expense-191.0K CHF-133.0K CHF-176.0K CHF
Exchange differences-2.8M CHF-1.6M CHF-1.5M CHF
Finance result, net-1.1M CHF1.5M CHF-599.0K CHF
Loss before tax-70.4M CHF-50.9M CHF-54.2M CHF
Income tax expense0 CHF-3.0K CHF-10.0K CHF
Loss for the period-70.4M CHF-50.9M CHF-54.2M CHF
Basic loss per share for the period attributable to equity holders-0.70 CHF-0.51 CHF-0.64 CHF
Diluted loss per share for the period attributable to equity holders-0.70 CHF-0.51 CHF-0.64 CHF

Compare AC Immune SA with another company

Recent filings

  1. Oct 9, 20263 PRIMARY DOCUMENT
  2. Oct 9, 20263/A
  3. Oct 2, 20266-K
  4. Sep 23, 20266-K
  5. Sep 3, 20266-K
  6. Aug 20, 20266-K
  7. Aug 11, 20266-K
  8. Aug 5, 20266-K
  9. Jun 30, 20266-K
  10. Jun 15, 20264 PRIMARY DOCUMENT
  11. Jun 15, 20264 PRIMARY DOCUMENT
  12. Jun 15, 20264 PRIMARY DOCUMENT
  13. Jun 15, 20264 PRIMARY DOCUMENT
  14. Jun 15, 20264 PRIMARY DOCUMENT
  15. Jun 11, 20266-K

Every filing from the last three years, summarized. The full record is on SEC EDGAR.1

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
    Yahoo FinanceACIU quote
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10